We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Inion Oy | IIN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.36 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.36 | 0.36 |
| Top Posts |
|---|
Posted at 11/8/2008 08:22 by pre Out-licensing agreement (Inion Oy)RNS Number : 0340B Inion Oy 11 August 2008 Inion Oy ("Inion or the "Company") Inion licenses bioactive bone regrowth technology to US company Curative Biosciences Inc. Tampere, Finland and Guildford, UK. 11 August 2008, Inion (LSE: IIN.L), today announces the signature of an out-licensing agreement with US company, Curative Biosciences Inc. (Waltham, MA), covering certain of its novel bioactive technologies for the promotion of bone regrowth and repair when treating patients undergoing orthopaedic surgical procedures. Under the terms of the licensing agreement, Curative Bioscience Inc. will pay to Inion a small upfront fee, development and sales milestones of up to US$2,025,000 and royalties on revenues generated from any products developed using the technology. The licensed technology is based on the use of N,N-dimethylacetamid pharmaceutically acceptable salts and prodrugs, either alone or incorporated in resorbable polymer structures (such as plates, membranes and screws) for implantation in patients. Patent applications covering this technology in the UK and internationally have been filed and are pending. Chris Lee, Inion's CEO, said: "DMA was discovered to have bioactive properties in promoting bone repair and regrowth through research work undertaken at our Cambridge facility prior to its closing last year. Inion, however, is no longer pursuing early stage development work in this area as it focuses on the commercialisation of its existing product portfolio for spinal surgery and orthopaedic trauma. By out-licensing non-core intellectual property and technologies, such as DMA, we seek to realise the value resulting from our research through companies more focused in these areas." -ends- For further information, please contact: Inion Oy Tel: +44 (0)1483 685390 Chris Lee, Chief Executive Officer Julien Cotta, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / David Dible About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. This information is provided by RNS The company news service from the London Stock Exchange END |
Posted at 15/7/2008 08:09 by pre Wonder how much this is worth to IIN....this will open up other markets imo, with the US already opening up imo:-))Found it! It estimates that the US market for these procedures is worth approximately 318 million euro and 32 million euro, respectively. |
Posted at 15/7/2008 08:06 by pre Cracking RNS....regulatory approval obtained:-)))))))Regulatory Approval (Inion Oy) RNS Number : 0510Z Inion Oy 15 July 2008 Inion Oy ("Inion or the "Company") Inion receives 510(k) marketing clearance to sell its biodegradable graft containment systems in the USA for spinal fusion procedures Tampere, Finland and Guildford, UK. 15 July 2008, Inion (LSE: IIN.L), the company focused on the development and commercialisation of novel biodegradable medical implants, today announces it has received 510(k) marketing clearance from the US Food and Drug Administration (FDA) for its biodegradable graft containment systems for spinal fusion procedures. The US marketing clearance has been received for the Inion S-1* Anterior Cervical Fusion System, the Inion S-1* double-level plate and the Inion S-2* Anterior Thoraco-Lumbar Fusion System. These systems consist of biodegradable plates and screws, which are designed for bone graft containment in spinal fusion procedures. Such procedures are carried out as a treatment for a range of spinal conditions including ruptures and displacement of inter-vertebral discs. Inion's S-1* and Inion S-2* graft containment systems include implants intended for use along the entire length of the spine in conjunction with traditional rigid fixation. These new graft containment systems also incorporate a radiographic marker to the edges of the plates and to the tips of screws. These markers enable surgeons to view the position of the implants in post-operative x-ray without interfering with their assessment of the site of surgery and its healing progress. More than 183,000 cervical plating procedures (Ref. 1) and more than 10,000 anterior thoraco-lumbar plating procedures (Ref. 2) were performed in 2006 in the USA. The US market for these procedures was worth approximately EUR318 million and EUR32 million, respectively. The number of spinal plating procedures has since grown at an annual rate of approximately 30%. Inion's biodegradable implants offer significant clinical benefits over traditional metal materials, primarily in that they slowly and completely degrade over time into carbon dioxide and water, which are absorbed into the body. The Inion S-1* and Inion S-2* graft containment systems received CE Mark marketing clearance in Europe in August 2007 and September 2007, respectively. Chris Lee, Inion's CEO, said: "The US marketing clearance for our biodegradable spine products is great news. We are already seeing increased uptake of this important product line in Europe where awareness and acceptance of the clinical benefits of biodegradable medical implants is rapidly growing among surgeons, who are adopting this technology into their practice. Our aim now is to push these new biodegradable products aggressively into the US spine market where we believe it will make an attractive alternative to traditional metal plates and a strong driver of value for the Company." References 1. Spinemarket, Inc: US spinal implant market: Cervical plate analysis. 2007 2. Spinemarket, Inc: US spinal implant market: Anterior lumbar plating analysis. 2007 -ends- For further information, please contact: Inion Oy Tel: +44 (0)1483 685390 Chris Lee, Chief Executive Officer Julien Cotta, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / David Dible About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. This information is provided by RNS The company news service from the London Stock Exchange END REAZGGMNGDLGRZZ |
Posted at 07/7/2008 08:13 by pre Let's see what today brings....a bullish trading update from IIN...we should see this advance further from here imo... |
Posted at 04/7/2008 09:32 by pre imo, this fall looks well overdone over the past few weeks....today IIN have announced a bulllish update and are showing increasing strength in overseas market which bodes well:-) |
Posted at 04/7/2008 08:24 by pre Pre-close Trading Update (Inion Oy)RNS Number : 3088Y Inion Oy 04 July 2008 Inion Oy ("Inion or the "Company") Pre-close Trading Update Tampere, Finland and Guildford, UK. 4 July 2008, Inion (LSE: IIN.L), the company focused on the development and commercialisation of novel biodegradable medical implants, today provides an update on 2008 trading, ahead of its half-yearly results announcement expected in August 2008. Based on the unaudited figures for the six months to 30 June 2008, the Directors anticipate that revenues for the period will be approximately EUR2.6 million, up 12% on the corresponding period in 2007. Invoiced sales of EUR1.8 million for the second quarter were 115% higher than in the first quarter of 2008, and 34% higher than in the corresponding period in 2007. These positive trends lead us to believe that Inion is on track to meet current market expectations of circa EUR7.0 million in sales for the full year 2008. Significantly, within these growth figures there is evidence to suggest Inion is starting to gain traction in the important US market. Chris Lee, Inion's CEO, said: "We continue to make good progress with executing our commercial strategy and are pleased to see sales growing strongly across our focused market segments. This uplift in sales is as a result of our commercial teams in these areas becoming more effective and an increasing awareness and acceptance among surgeons of the clinical benefits our biodegradable products can bring." -ends- For further information, please contact: Inion Oy Tel: +44 (0)1483 685390 Chris Lee, Chief Executive Officer Julien Cotta, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / David Dible About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. This information is provided by RNS The company news service from the London Stock Exchange END TSTFKNKDOBKDQOK |
Posted at 13/11/2006 17:45 by egoi Rumours elsewhere that Corin (CRG) are about to make an acquisition. Seems to me IIN would be a possible target, so maybe not an MBO but conceivably a bidder. I have no position in either but used to hold IIN. |
Posted at 31/8/2006 18:22 by contrarian2investor david77,I have been watching this stock every since it was bought in Bloomberg Money for its Stockwatch portfolio at £1.11. They stated that is was a high risk recovery play at the time. It has proven to be the case. However from the ashes I believe a recovery could finally take place in the form of a restructuring or a takeover. I will be waiting to hear what the board has to say next week before I decide whether to make a small investment. Unfortunately its generally been a bad market for most stocks from Finland and IIN seems to have been hammered. Your's with integrity, C2I |
Posted at 13/12/2004 01:42 by happe This should be IIN thread, please. |
Posted at 23/4/2001 15:43 by aquila energyi - thanks for that link but when i tried it everything ground to a halt and screaming, wailing and gnashing of teeth was heard from with my pc...I'll keep trying though!I just wondered if there was any iinterest in this AFN /iin debate...regards, A. No action in iin so doesn't seem very probable .... |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
